Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study
Early initiation of GLP-1 receptor agonists in patients with diagnosed T2DM was associated with a modest reduction in overall cancer risk, particularly among individuals with obesity. These findings highlight the dual metabolic and oncologic value of prompt GLP-1 RA therapy.
Authors
- Cheng‐Hsun Chuang (ORCID: https://orcid.org/0000-0002-4571-3608)
- Ping‐Kun Tsai (ORCID: https://orcid.org/0000-0003-4346-1926)
- Yu‐Hsun Wang (ORCID: https://orcid.org/0000-0002-4937-6119)
- Shih-Wen Kao
- Chao‐Bin Yeh (ORCID: https://orcid.org/0000-0002-3978-5576)
Institutions
- Tri-Service General Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- National Defense Medical Center (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-12-02
- DOI
- https://doi.org/10.32604/or.2025.072875
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00